Skip to main content

Latest news stories

Latest news stories

23-08-2019 | FDA | News

Entrectinib gains two indications in USA

Details of this FDA decision are a click away

21-08-2019 | Renal cell carcinoma | News

Long-term benefit of nivolumab plus ipilimumab shown in advanced RCC

Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.

20-08-2019 | Nausea and vomiting | News

Study supports use of fosnetupitant in combination with palonosetron for CINV

A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

19-08-2019 | FGFR inhibitors | Highlight | News

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

16-08-2019 | EMA | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

15-08-2019 | Urothelial cancer | News

Gemcitabine–eribulin shows promise for cisplatin-ineligible urothelial carcinoma

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

14-08-2019 | Non-small cell lung cancer | News

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

13-08-2019 | Prostate cancer | Highlight | News

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

12-08-2019 | Checkpoint blockade | News

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

09-08-2019 | Prostate cancer | News

‘Superior’ detection of biochemical recurrence with PSMA PET–CT

68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

08-08-2019 | Venous thromboembolism | News

ASCO updates VTE prophylaxis, treatment guidelines

Updated clinical practice guidance on the prophylaxis and treatment of venous thromboembolism in patients with cancer is now available from ASCO.

08-08-2019 | Urothelial cancer | News

Balance needed for short- vs long-term immunotherapy risks, benefits in mUC

Patients with cisplatin-ineligible metastatic urothelial carcinoma have decreased short-term overall survival when receiving immunotherapy versus carboplatin-based chemotherapy in the first line, but increased long-term survival, study findings indicate.

07-08-2019 | EMA | News

Larotrectinib first tumor-agnostic treatment to get EMA nod

Click through for the details of this decision

05-08-2019 | Prostate cancer | Highlight | News

HIV infection associated with worse prostate cancer outcomes

Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.

02-08-2019 | Non-small cell lung cancer | News

LIPI score associated with survival in metastatic NSCLC irrespective of treatment

An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.

02-08-2019 | FDA | News

Darolutamide added to armamentarium for nonmetastatic CRPC

Read more about this US FDA approval here

31-07-2019 | Nivolumab | News

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

30-07-2019 | Prostate cancer | News

Decision aids unlikely to influence men considering prostate cancer screening

Current decision aids probably have no influence on whether physicians and patients discuss prostate cancer screening or decide to undergo screening, according to a systematic review and meta-analysis.

26-07-2019 | Non-small cell lung cancer | News

Hurricane disruption quantified for lung cancer radiotherapy

Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.

24-07-2019 | Erdafitinib | Highlight | News

Erdafitinib shows promising efficacy in advanced urothelial carcinoma

The pan-FGFR inhibitor erdafitinib could be a treatment option for previously treated patients with locally advanced or metastatic urothelial carcinoma harboring FGFR aberrations, suggest phase II trial results.

Image Credits